Compare Pfizer Inc (PFE) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs SYSCO Corporation — how do they compare? Pfizer Inc trades at $27.91 (market cap $158.39B), while SYSCO Corporation trades at $81.58 (market cap $38.25B). The key difference: Pfizer Inc is far larger — about 4.1× SYSCO Corporation's market cap, and Pfizer Inc pays the higher dividend (6.19%). Which is the better fit depends on your goals.
| PFE | SYY | |
|---|---|---|
Market Cap | $158.39B | $38.25B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Staples |
52-Week High | $29.02 | $91.16 |
52-Week Low | $23.60 | $69.30 |
Enterprise Value | $209.89B | $51.43B |
Dividend Yield | 6.19% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.
Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.
Sysco Corporation (SYY) trades at $79.84, down 0.26% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported solid Q2 2026 earnings beat ($1.53 vs $1.51 expected) and maintains strong revenue growth, reaching $81.37B in 2025. Recent news highlights the company's $500M AI efficiency program and reaffirmed fiscal 2027 guidance, while analysts maintain a 60% buy rating with $88.25 consensus target.
Sysco presents a compelling investment case with attractive valuation (P/S 0.45), strong institutional interest, and AI-driven efficiency initiatives. However, risks include integration challenges from the Jetro Restaurant Depot acquisition, rising debt levels, and margin pressure from inflationary costs. The stock offers 10% upside to analyst targets but requires monitoring of execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
